Organogenesis Holdings
Open
$2.34
Prev. Close
$2.34
High
$2.36
Low
$2.34
Market Snapshot
$301.02M
-16.1
-0.02
$482.04M
854
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 854 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 854 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.
Recently from Cashu
PuraPly AM Shows Significant Improvement in Wound Closure in Recent Clinical Trial
In a significant development for Organogenesis Holdings, recent findings from a clinical trial showcase the efficacy of its product, PuraPly AM, in enhancing wound healing when used in conjunction wit…
Anticipation Grows for Organogenesis Holdings' Earnings Report Amidst Regenerative Medicine Innovation
Anticipation Builds Ahead of Organogenesis Holdings' Earnings Report Organogenesis Holdings (NASDAQ:ORGO) gears up to disclose its quarterly earnings report on February 26, 2026. This announcement sig…
Organogenesis Holdings to Report Earnings, Highlighting Future Growth in Regenerative Medicine
Anticipating Innovative Growth Organogenesis Holdings prepares to unveil its quarterly earnings report on February 26, 2026, marking a pivotal moment for the company as it continues to establish itsel…
Organogenesis Holdings: Innovating in Regenerative Medicine Despite Market Challenges
Organogenesis Holdings: Navigating the Therapeutic Landscape Amidst Market Challenges Organogenesis Holdings, a leader in the regenerative medicine sector, continues to focus on innovation and product…